No matter where you live, what you look like or what’s in your wallet, everyone gets sick. And all of us should have the medicine we need to lead healthy lives.
WASHINGTON (March 26, 2020) – The United States Senate just passed a $2 trillion stimulus bill in response to the coronavirus crisis in the United States. The legislation includes provisions to support hospitals, small businesses and distressed companies caught in the public health and economic fallout from the pandemic.
The following is a statement from Margarida Jorge, national campaign director for Lower Drug Prices Now:
“This package is a step towards helping Americans stay healthy and get back on their feet in the midst of the coronavirus crisis.
Instead, Drug Should Come With Affordability Guardrails
Statement from Margarida Jorge, Campaign Director, Lower Drug Prices Now
Washington, DC (March 24, 2020) — Yesterday the Trump Administration gave the drug corporation Gilead Sciences special monopoly protection on the promising COVID-19 treatment Remdesivir, giving them a green light to price gouge on a desperately needed treatment.
It’s especially outrageous considering the significant public investment taxpayers have made to the research and development of Remdesivir by the United States Army Medical Research Institute of Infectious Diseases and the Centers for Disease Control.
WASHINGTON (March 20, 2020) – Since the start of the coronavirus COVID-19 outbreak in the U.S. the Lower Drug Prices Now Coalition has been sounding the alarm about potential Big Pharma price gouging if President Trump and Health and Human Services Secretary Azar fail to enact price control measures that ensure affordability.
To listen to the press conference, click: Audio recording (speaking begins at 3:30 mark) of the press conference
(Des Moines, Iowa, March 18, 2020) — We hear a lot from national sources about the continuing needs, concerns and spread of the COVID-19 virus. Today we heard from real Iowans representing Iowa government, small business, healthcare, and senior communities about the effects in Iowa.
No matter where people live, what they look like or what’s in their wallets, at some point everyone is going to get sick and need prescription medicines. Whether it’s a sore throat, high blood pressure or cancer, everyone needs affordable medicine to lead healthy lives.
But today, drug corporations and their powerful Pharma lobbyists are standing in the way of our health and economic security. By jacking up prices to boost profits, they are forcing people to make stark choices – like choosing between medicine and other necessities, or going without treatment, or going into debt or watching loved ones suffer without the drugs they need to get better.
It doesn’t have to be this way. Together, we can change the system to make sure everyone gets access to medicines they can afford. We are a coalition that has come together to fight for transformative, bold reforms through legislative, legal and executive actions at the state and federal level based on these four principles:
It is our government’s responsibility to guarantee that everyone in the United States, no matter where they live, what they look like or how much money they have, can afford the medicines they need to stay healthy and take care of their families. We oppose policies that put medicine out of reach for Americans or that deny or delay access to medicine for people in other countries.
Drug corporations and their lobbyists have rigged the rules of the pharmaceutical industry in order to drive up profits, putting medicines out of reach for millions of people. Their price gouging makes health and economic disparities even worse by putting the greatest pressure on the people who can least afford to bear the brunt of high prices. We must topple the barriers that systematically deny people access to medicines so that no one is left behind.
We must curb drug corporations’ power to extract profits at the expense of people’s health by harnessing the government’s power to improve patients’ lives. This requires a range of concrete steps that re-write the rules to rein in drug corporations’ monopoly power to price gouge; that requires the drug industry to negotiate fair prices with government; and that holds corporations accountable for practices that directly and indirectly keep prices unjustifiably high.
We as taxpayers help foot the bill for a substantial amount of drug research, development and innovation, for drug purchasing through Medicare, Medicaid, and the Veterans Administration and for marketing, legal and patent protections for drug corporations. We must ensure government funding and incentives prioritize medical breakthroughs that most serve the public good rather than those that primarily extend monopolies and increase corporate profits. Everyone wants proven treatments and life-saving innovations, but prescription drugs are useless to people who can’t afford them. We must change the system to make sure everyone can benefit from our shared public investment in new drug research and development by ensuring that medicines are affordable and accessible to everyone.